Not a good buy right now: price is testing/breaking key support (~44.63) while momentum (MACD) is still deteriorating.
Upside exists vs. Street targets ($52–$59), but near-term tape/positioning is mixed-to-bearish (heavy put volume) and there are no proprietary “strong buy” signals today.
For an impatient buyer, the risk/reward at 44.56 is not compelling until BN either (1) reclaims the pivot ~46.11 or (2) flushes closer to the next support ~43.72 and stabilizes.
Current (pre-market): 44.56 (-0.16%), sitting at/just below S1 support 44.632; next downside level S2 43.721.
Momentum: MACD histogram -0.238 and negatively expanding → bearish momentum is strengthening, consistent with a short-term downtrend.
RSI(6) ~30.64 → near-oversold/weak; can bounce, but not a confirmation by itself.
Moving averages: “converging” → trend is indecisive, but with MACD worsening and price under pivot (46.106), bias remains bearish-to-neutral.
Key levels: Pivot 46.106 (must reclaim for trend improvement), Resistance R1 47.58, R2 48.491; Support S1 44.632, S2 43.721.
Pattern-based forward drift: similar-pattern stats imply modest upside next week (+0.41%) but slightly negative next month (-0.6%), supporting a choppy/weak near-term bias.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Sentiment split: OI put/call 0.55 is generally bullish/less defensive positioning, but today’s put/call volume 24.47 is extremely put-heavy → strong near-term demand for puts (bearish speculation or heavy hedging).
Activity spike: today’s volume 4,049 is 212% of 30-day avg; open interest also elevated vs avg (168%) → options traders are unusually active.
Volatility: 30D IV ~24.38 with very low IV percentile (4.8) / IV rank (11.57) → options are relatively cheap vs its own history; the market is not broadly pricing a big move, despite the put-volume surge.
Technical Summary
Sell
8
Buy
3
Positive Catalysts
Potential catalyst ahead: QDEC 2025 earnings on 2026-02-12 (pre-market) could reset sentiment.
Neutral/Negative Catalysts
increases probability of a move toward S2 (~43.72).
Revenue: 18.917B, down -8.27% YoY → top-line contraction.
Gross margin: 22.65, down -11.52% YoY → profitability pressure at the gross level.
Net income: 177M, up +742.86% YoY; EPS: 0.08, up +700% YoY → sharp bottom-line improvement, likely influenced by non-linear items (given revenue/margin declines) but still supportive of earnings optics.
Overall: mixed quality quarter (weaker sales/margins, much stronger EPS/NI).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Trend: consistently positive and improving—recent price target raises and continued Buy/Outperform/Overweight ratings.
2026-01-27 Morgan Stanley: Overweight; PT raised to $58 from $54; expects ramping deal activity to support alt managers into Q4/2026; raised EPS estimates.
2025-12-15 RBC: Outperform; PT raised to $58 from $57; named BN a Top Pick for 2026; cites upside catalysts (carried interest realizations) and defensive attributes.
2025-11-14 TD: Buy; PT raised to $59 from $57; highlights AI infrastructure/renewables angle.
2025-11-14 CIBC: Outperformer; PT raised to $52 from $50.67; sees continued delivery.
Wall Street pros vs cons: Pros—clear consensus bullishness and multiple catalysts into 2026; Cons—near-term technical weakness and mixed quarter quality (revenue/margin down) may delay the market “paying up” for the story.
Wall Street analysts forecast BN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BN is 49.91 USD with a low forecast of 36 USD and a high forecast of 59 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast BN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BN is 49.91 USD with a low forecast of 36 USD and a high forecast of 59 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.310
Low
36
Averages
49.91
High
59
Current: 44.310
Low
36
Averages
49.91
High
59
Morgan Stanley
NULL -> Overweight
maintain
$54 -> $58
AI Analysis
2026-01-27
Reason
Morgan Stanley
Price Target
$54 -> $58
AI Analysis
2026-01-27
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Brookfield Corp. to $58 from $54 and keeps an Overweight rating on the shares. Ramping deal activity should be supportive for the alternative asset managers into Q4 and 2026, says the analyst, who raised EPS estimates by 4% and 1% ahead of consensus on average among the group as part of the firm's Q4 earnings preview.
RBC Capital
Outperform
maintain
$57 -> $58
2025-12-15
Reason
RBC Capital
Price Target
$57 -> $58
2025-12-15
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Brookfield Corp. to $58 from $57 and keeps an Outperform rating on the shares as part of its broader research note previewing 2026 across North American Diversified Financials. The firm also names the stock its Top Pick for next year. Brookfield is among the companies that provide upside catalysts in 2026 in a favorable macro environment as well as defensive attributes in the event of macro volatility, the analyst tells investors in a research note. RBC adds that the market is still overly discounting the business despite tailwinds into 2026, most notably carried interest realizations.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BN
